Immutep Limited (ASX:IMM) Reports Q3 FY25 Milestones and Financial Position
Immutep Limited (ASX:IMM) announces significant clinical trial milestones and maintains a robust cash position in its Q3 FY25 report.
Category: Companies
Health and Plant Protein Group Limited (ASX:HPP) Releases FY25 Q3 Activities Report
Health and Plant Protein Group Limited (ASX:HPP) releases FY25 Q3 report, highlighting cash flow and ongoing IRS repayment efforts.
BrainChip Holdings Ltd (ASX:BRN) Releases Q1 2025 Activities Report
BrainChip Holdings Ltd (ASX:BRN) releases Q1 2025 report, highlighting key partnerships and a solid financial position.
G8 Education Limited (ASX:GEM) Announces 2025 AGM Highlights
G8 Education Limited (ASX:GEM) reports a 14.8% EBIT increase and highlights strategic initiatives during its 2025 AGM.
Donaco International Limited (ASX:DNA) Reports Q3 FY2025 Results and Announces Share Acquisition Scheme
Donaco International (ASX:DNA) announces Q3 FY2025 results and a share acquisition Scheme Implementation Deed to strengthen its cash position.
Radiopharm Theranostics (ASX:RAD) Begins Phase 2b U.S. Trial for 18F-RAD101
Radiopharm Theranostics (ASX:RAD) initiates Phase 2b U.S. trial of 18F-RAD101, advancing diagnostic capabilities for brain metastasis.
Unibail-Rodamco-Westfield (ASX:URW) Announces Q1 2025 Trading Update
Unibail-Rodamco-Westfield (ASX:URW) reports strong Q1 2025 performance, confirms earnings guidance, and completes significant asset disposals.
Sayona Mining Limited (ASX:SYA) Reports High-Grade Lithium Drill Results
Sayona Mining (ASX:SYA) announces substantial high-grade lithium drill results, enhancing the resource potential of its Moblan Lithium Project.
Hansen Technologies Ltd (ASX:HSN) Acquires Strategic Assets in Germany
Hansen Technologies (ASX:HSN) acquires strategic software assets in Germany for A$13.4m, enhancing its market position and growth strategy.
Coventry Group Ltd (ASX:CYG) Announces Q3 FY25 Trading Update
Coventry Group Ltd (ASX:CYG) reports a 3.6% sales increase in Q3 FY25, despite a 41.1% drop in EBITDA, outlining strategic cost reductions for improved margins.